RxDoctor Payments Data

Michael Orsini, MD

Otolaryngology · Sewickley, PANPI 1548235112

Payments from drug & device makers

$4,705in general payments, 2019–2025

Across 164 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$927
  • Optinose US, Inc.$740
  • Regeneron Healthcare Solutions, Inc.$648
  • Sanofi$378
  • ARS Pharmaceuticals Operations, Inc.$375
  • Novo Nordisk$281
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,705 in reported general payments places this provider in the 80th percentile of 456 otolaryngology providers in Pennsylvania.

See all otolaryngology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$119,970
Medicare patients
483
Services billed
4,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine120$26,654
XhanceFluticasone Propionate14$10,593
Fluticasone Propionate275$5,040
Breo ElliptaFluticasone/Vilanterol12$4,537
Ipratropium Bromide96$4,029
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort65$3,795
Montelukast Sodium213$3,465
Azelastine Hcl88$2,709
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth19$2,290
Famotidine143$1,583
Ofloxacin49$1,229
Betamethasone Dipropionate38$911
Albuterol Sulfate HfaAlbuterol Sulfate14$649
Mupirocin38$373
Omeprazole15$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$18$26,654120 claims
Optinose US, Inc.Xhance$740$10,59314 claims
GSKBreo Ellipta$927$4,53712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 456 otolaryngology providers in Pennsylvania.

Other otolaryngology in Sewickley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →